MG53 and GsdmD interaction to protect heart cells after a heart attack
Official title: Interactions of MG53 and GsdmD for Neutrophil Pyroptosis Inhibition
Funded at St. John's University · NIH-11402588 · Data updated 2026-11-12
A study to see if MG53 can team up with GsdmD to reduce inflammatory cell death and limit heart damage after a heart attack.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | St. John's University NIH-funded |
| Lab location | 1 site (Queens, United States) |
| Project start | September 1, 2025 |
| Project end | May 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $155,463 |
| NIH project number | 5R16GM153571-02 |
| Project ID | NIH-11402588 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients who have had or are at risk for myocardial infarction and related inflammatory conditions may be relevant for future trials or related studies.
✕Less likely to help
People without heart disease or those not connected to inflammatory responses after heart injury may not benefit.
What this research studies
If you’ve had a heart attack, inflammation can worsen heart damage. This project looks at MG53, a natural membrane repair protein, and how it might stop a deadly inflammatory process called pyroptosis by interacting with GsdmD in neutrophils. Researchers will explore how MG53 and GsdmD interact before and after GsdmD activates, to see if this can calm the inflammatory response. The goal is to find a safe way to promote healing after a heart attack by reducing harmful cell death. The work is done at St. John’s University with a specific emphasis on heart cells, blood immune cells, and related tissues.
Why it matters
Potential benefit: If successful, this could lead to therapies that lessen inflammation and tissue damage after a heart attack, improving recovery.
How similar studies have gone: Preliminary data suggest MG53 can reduce pyroptosis and improve heart damage after MI, showing potential but needing direct confirmation.
Where this research is happening
-
St. John's University
Queens, United States Active
Researchers
- Principal investigator: Wang, Shanzhi — St. John's University
- Study coordinator: Wang, Shanzhi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.